Protective Effects of a Protein-Bound Polysaccharide, PSK, Against Candida albicans Infection in Syngeneic Tumor-Bearing Mice via Th1 Cell Functions

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 5, 2003, Pages 769-780

  Ohmura, Yoshio ^a   Matsunaga, Kenichi ^a   Motokawa, Isamu ^a   Sakurai, Katsuo ^a   Ando, Takao ^a  

^a KUREHA CORPORATION   (Japan)

Author keywords

Candida albicans infection; CD4 positive cells; Elispot assay; IFN ; IL 12; Intracellular cytokine level; PSK; Th1 cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; KRESTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL; TH1 CELL;

EID: 0242413793     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803770418319     Document Type: Article

References (31)

1. Drouhet E. Historical introduction. In: Ajello L, Hay JR, Toply & Wilson's Microbiology and Microbial Infections. Vol. 4, Medical Mycology. London: Arnold, 1998:3.
2. Walsh TJ. Yeast infections in the immunocompromised host. In: Howard MH, Miller JD, The Mycota VI. Human and Animal Relationships. Berlin-Heidelberg: Springer Verlag, 1996:117.
3. Denning DW. Trends in management of systemic fungal infection. Chemotherapy 1992;38(suppl. 1):S1.
4. Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997;16:51.
5. Miyake T, Takeya K, Nomoto K, Muraoka S. Cellular elements in the resistance to candida infection in mice I. Contribution of T lymphocytes and phagocytes at various stages of infection. Microb Immunol 1977;21:703.
6. Cenci E, Romani L, Vecchiarelli A, et al. T cell subsets and IFN-γ production in resistance to systemic candidiasis in immunized mice. J Immunol 1990;144:4333.
7. Romani L. The T cell response against fungal infections. Curr Opin Immunol 1997;9:484.
8. O'Garra A. Cytokines induce the development of functionally heterogenous T helper cell subsets. Immunity 1998;8:275.
9. Kobayashi H, Matsunaga K, Oguchi Y. Anti-metastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes, an overview. Cancer Epidemiol Biomarkers Prev 1995;4:275.
10. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994;343:1122.
11. Mitomi T, Tsuchiya S, Iijima N, et al. Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 1992;35:123.
12. Tsukagoshi S, Hashimoto Y, Fujii G, et al. Krestin (PSK). Cancer Treat Rev 1984;11:131.
13. Uetsuka A, Satoh S, Ohno Y. Protective effect of PSK, a protein-bound polysaccharide preparation against candidiasis in tumor-bearing mice. In: Escobar MR, Friedman H, eds. Macrophages and Lymphocytes, Part B. New York: Plenum Press, 1980:21.
14. Ohmura Y, Matsunaga K, Motokawa I, et al. Protective effects of a protein-bound polysaccharide, PSK, on Candida infection in mice via tumor necrosis factor-α induction. Int Immunopharm 2001;1:1797.
15. Chromczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156.
16. Harada M, Tamada K, Abe K, et al. Role of the endogenous production of interleukin 12 in immunotherapy. Cancer Res 1998;58:3073.
17. Svetic A, Finkelman FD, Jian YC, et al. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J Immunol 1991;147:2391.
18. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998;188:2357.
19. Fallarino F, Grohmann U, Bianchi R, et al. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication. J Immunol 2000;165:5495.
20. Nagai H, Hara I, Horikawa T, et al. Elimination of CD4+ T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J Invest Dermatol 2000;115:1059.
21. Nishimura T, Nakui M, Satoh M, et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000;46:S52.
22. Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4+ T-regulatory cells and systematic collapse of antitumor immunity. Immunology 2001;103:449.
23. Hirose K, Zachariae COC, Oppenheim JJ, Matsushima K. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 1990; 9:475.
24. Abe Y, Miyake M, Horiuchi A, et al. Induction of cytokines by polysaccharide K in the peripheral blood mononuclear cell culture. J Clin Exp Med 1990; 152:617.
25. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 1993;14:335.
26. Endoh H, Matsunaga K, Yoshikumi C, et al. Production of antiserum against antitumor protein-bound polysaccharide preparation, PSK (Krestin) and its pharmacological application. Int J Immunopharmacol 1988; 10:103.
27. Harada M, Matsunaga K, Oguchi Y, et al. The involvement of transforming growth factor β in the impaired antitumor T cell response at gut-associated lymphoid tissue (GALT). Cancer Res 1995;55:6146.
28. 2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995;181:775.
29. Matsunaga K, Hosokawa A, Oohara M, et al. Direct action of a protein-bound polysaccharide, PSK, on transforming growth factor β. Immunopharmacology 1998; 40:219.
30. Nakamura K, Matsunaga K. Susceptibility of natural killer (NK) cells to reactive oxygen species (ROS) and their restoration by the mimics of superoxide dismutase (SOD). Cancer Biother Radiopharm 1998;13:275.
31. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1994;1:447.